- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
E-Z-EM introduces new bowel agent
Gastrointestinal contrast agent developer E-Z-EM of Westbury,NY, has introduced a new product targeted at improving visualizationof the small bowel in x-ray studies. E-Z-EM's Entero Vu agentenables "see-through" imaging of the small bowel,
Gastrointestinal contrast agent developer E-Z-EM of Westbury,NY, has introduced a new product targeted at improving visualizationof the small bowel in x-ray studies. E-Z-EM's Entero Vu agentenables "see-through" imaging of the small bowel, inwhich the translucency of the intestine is maintained even throughmultiple organ layers. Entero Vu allows radiologists to obtaina clear study of the entire small bowel, according to the company.
E-Z-EM claims that Entero Vu offers clearer images than small-bowelstudies using conventional oral contrast media, which often lackdefinition and detail because of the high density of the media.Because it is administered orally, Entero Vu is also easier tohandle than another small-bowel imaging procedure, enteroclysis,in which contrast is directly infused into the small intestinevia a catheter.
E-Z-EM has set a list price of $198 for a box of Entero Vu, whichconsists of 12 doses.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
